| scholarly article | Q13442814 |
| P50 | author | Neil Pearce | Q37392568 |
| Richard Beasley | Q37838402 | ||
| Julian Crane | Q109339423 | ||
| P2093 | author name string | Burgess C | |
| Grainger J | |||
| Woodman K | |||
| Keane A | |||
| P2860 | cites work | Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 |
| Estimability and estimation in case-referent studies | Q34169256 | ||
| Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81 | Q34647199 | ||
| Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study | Q34667831 | ||
| A case-control study of deaths from asthma. | Q36159914 | ||
| Asthma mortality in New Zealand: a two year national study | Q39360149 | ||
| Comparison of four weeks' treatment with fenoterol and terbutaline aerosols in adult asthmatics *1A double-blind crossover study | Q41049638 | ||
| PAF antagonists in asthma | Q43838443 | ||
| Fenoterol and fatal asthma | Q44785611 | ||
| Fenoterol and fatal asthma | Q68082262 | ||
| Fenoterol and fatal asthma | Q68085940 | ||
| Multicentre randomised clinical trial of chorion villus sampling and amniocentesis. First report. Canadian Collaborative CVS-Amniocentesis Clinical Trial Group | Q69366946 | ||
| Accuracy of certification of deaths due to asthma. A national study | Q69654193 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | New Zealand | Q664 |
| asthma | Q35869 | ||
| P304 | page(s) | 105-111 | |
| P577 | publication date | 1991-02-01 | |
| P1433 | published in | Thorax | Q7796158 |
| P1476 | title | Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study | |
| P478 | volume | 46 |
| Q49888779 | A CREB-mediated increase in miRNA let-7f during prolonged β-agonist exposure: a novel mechanism of β2-adrenergic receptor down-regulation in airway smooth muscle |
| Q41232825 | Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol |
| Q35627643 | Adverse effects of beta-agonists: are they clinically relevant? |
| Q40040431 | After asthma: redefining airways diseases. |
| Q43614151 | Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies |
| Q32032696 | Are asthma medications and management related to deaths from asthma? |
| Q38178784 | Are inhaled longacting β2 agonists detrimental to asthma? |
| Q34744026 | Asthma and allergy: a worldwide problem of meanings and management? |
| Q33821265 | Asthma and the beta agonist debate |
| Q35532670 | Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. |
| Q57153356 | Asthma deaths in New Zealand |
| Q42987017 | Asthma deaths in New Zealand |
| Q84478552 | Asthma in adults |
| Q84546527 | Asthma in adults |
| Q26341898 | Asthma mortality in California, 1960-1989. Demographic patterns and occupational associations |
| Q39461055 | Asthma mortality in Columbia |
| Q38569448 | Asthma mortality: another opinion--is it a matter of life and ... bread? |
| Q73468150 | Asthma mortality: the worldwide response |
| Q35076452 | Asthma pharmacogenetics and the development of genetic profiles for personalized medicine |
| Q33930453 | Asthma--the changing face of drug therapy |
| Q35258458 | Beta 2 adrenergic receptors in asthma: a current perspective |
| Q34994944 | Beta-agonists |
| Q40903671 | Bronchodilator treatment and deaths from asthma: case-control study. |
| Q43210483 | Bronchodilators: wrong for the lung in the long run? |
| Q41850857 | Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers |
| Q41147911 | Cardiovascular effects of fenoterol under conditions of hypoxaemia |
| Q34747095 | Case-control study of salmeterol and near-fatal attacks of asthma |
| Q39218896 | Chronic respiratory illness as a predictor of survival in idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study |
| Q36645453 | Clinical concerns with inhaled beta2-agonists: adult asthma |
| Q30416723 | Clinical pharmacology of asthma. Implications for treatment |
| Q36532473 | Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients |
| Q71673452 | Concerns regarding the current use of beta-agonists in the therapy of asthma |
| Q67525282 | Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma |
| Q43783364 | Current controversies in asthma treatment. |
| Q53219510 | Current issues with beta2-adrenoceptor agonists: historical background. |
| Q28732772 | Data sharing: not as simple as it seems |
| Q35537305 | Deaths certified as asthma and use of medical services: a national case-control study |
| Q53364240 | Deaths from asthma in Italy (1974-1988): is there a relationship with changing pharmacological approaches? |
| Q57131860 | Demographic characteristics of patients experiencing near-fatal and fatal asthma: results of a regional survey of 400 asthma specialists [see comment] |
| Q71673477 | Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma |
| Q28360825 | Double trouble: impact of inappropriate use of asthma medication on the use of health care resources |
| Q36501291 | Effect of regular terbutaline on the airway response to inhaled budesonide |
| Q35026498 | Effects of beta 2-agonist- and dexamethasone-treatment on relaxation and regulation of beta-adrenoceptors in human bronchi and lung tissue |
| Q57153074 | End of the New Zealand asthma mortality epidemic |
| Q77325180 | Experience of an emergency mobile asthma treatment programme |
| Q38167643 | GPCRs and arrestins in airways: implications for asthma |
| Q57986761 | Gas chromatographic-mass spectrometric determination of ß2-agonists in postmortem blood: application in forensic medicine |
| Q42772710 | Genetic variability of the beta2 adrenergic receptor and asthma exacerbations |
| Q50674972 | How the practice of allergy shows the promise and challenge of personalized medicine. |
| Q35252017 | Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance? |
| Q88542181 | Inhaled steroids with and without regular salmeterol for asthma: serious adverse events |
| Q35187262 | Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma |
| Q33944522 | Interactions between corticosteroids and beta agonists |
| Q35273673 | Issues and advances in the pharmacotherapy of asthma |
| Q40388175 | Long- versus short-acting beta 2-agonists. Implications for drug therapy |
| Q35627925 | Long-acting beta2-agonists: comparative pharmacology and clinical outcomes |
| Q43834646 | Lower arrythmogenic risk of low dose albuterol plus ipratropium |
| Q33604844 | Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned? |
| Q44983716 | Myocardial injury during standard treatment of an adult with status asthmaticus |
| Q57153299 | Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics |
| Q36890928 | Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic |
| Q36346376 | Overcoming gaps in the management of asthma in older patients: new insights |
| Q39373220 | Patterns of Asthma Death and Near-Death in an Inner-City Tertiary Care Teaching Hospital |
| Q37425660 | Pharmacogenetics and the development of personalized approaches for combination therapy in asthma |
| Q36998191 | Pharmacogenetics of the beta 2-adrenergic receptor gene |
| Q43766164 | Potentially fatal asthma |
| Q55520201 | Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. |
| Q35026292 | Protection by dexamethasone of the functional desensitization to beta 2-adrenoceptor-mediated responses in human lung mast cells |
| Q35564039 | Psychological, social and health behaviour risk factors for deaths certified as asthma: a national case-control study. |
| Q43959176 | Racemic salbutamol administration to guinea-pigs selectively augments airway smooth muscle responsiveness to cholinoceptor agonists |
| Q71810390 | Rapid Onset of Tolerance to the Bronchoprotective Effect of Salmeterol |
| Q35277314 | Recent advances in asthma |
| Q24202005 | Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events |
| Q24241453 | Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events |
| Q24200353 | Regular treatment with formoterol for chronic asthma: serious adverse events |
| Q24241250 | Regular treatment with formoterol for chronic asthma: serious adverse events |
| Q24201048 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events |
| Q24240282 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events |
| Q24199079 | Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events |
| Q24241740 | Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events |
| Q24241960 | Regular treatment with salmeterol for chronic asthma: serious adverse events |
| Q35534866 | Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma |
| Q77534732 | Regulation of human mast cell and basophil function by cAMP |
| Q73738241 | Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994 |
| Q44260780 | Risk of myocardial ischaemia and beta-adrenoceptor agonists |
| Q33775459 | Risk of severe life threatening asthma |
| Q33775482 | Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity |
| Q35250822 | Risks versus benefits of inhaled beta 2-agonists in the management of asthma |
| Q37869146 | Safe use of long-acting β-agonists: what have we learnt? |
| Q42593042 | Safety of β2-Agonists in Asthma: Linking Mechanisms, Meta-Analyses and Regulatory Practice |
| Q40713319 | Salmeterol: an inhaled beta 2-agonist with prolonged duration of action |
| Q33604623 | Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline |
| Q41436218 | Stabilization of asthma mortality |
| Q34345856 | Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma |
| Q41719837 | Sympathomimetic enantiomers and asthma |
| Q36573494 | Systemic effects of salbutamol and salmeterol in patients with asthma |
| Q39481325 | The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology |
| Q39464358 | The beta-agonist controversy |
| Q54942896 | The current debate concerning beta-agonists in asthma: a review. |
| Q57152932 | The decline in asthma hospitalisations in persons aged 0-34 years in New Zealand |
| Q36028379 | The myocardial effects of fenoterol, isoprenaline and salbutamol in normoxic and hypoxic sheep. |
| Q33860221 | The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists |
| Q37550543 | Therapeutic management of allergic diseases. |
| Q47824258 | Thorax at 70. |
| Q35563595 | Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects |
| Q40520444 | Tolerance with beta 2-adrenoceptor agonists: time for reappraisal |
| Q34453206 | Understanding airway wall remodeling in asthma: a basis for improvements in therapy? |
| Q74031298 | [Has the symptomatology of asthma in the child changed over the last 30 years?] |
| Q80703047 | [Mortality and beta-agonists, or the risk of statistical inference] |
| Q54102662 | [The evolution of mortality due to asthma in the age groups 5-34 and 5-44. Spain, 1975-1991]. |
| Q71843751 | β2‐adrenergic agonists, corticosteroids and IgE production |
Search more.